H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Intellia Therapeutics (NTLA) to $18 from $25 and keeps a Buy rating on the shares. The FDA placed a clinical hold on nexiguran ziclumeran Phase 3 trials following the previously disclosed Grade 4 liver event, the analyst tells investors in a research note. The reduced the probability of approval to 30% from 40% for transthyretin amyloidosis indications.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics Faces FDA Clinical Hold on Trials
- Cathie Wood Boosts Biotech Bets, Cuts Back on Tech Favorites, Including Shopify and Palantir (PLTR)
- Cathie Wood’s ARK Investment buys 479.4K shares of Intellia Therapeutics today
- Unusually active option classes on open October 28th
- Warner Bros. Discovery upgraded, F5 downgraded: Wall Street’s top analyst calls